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Analysis of the functional muscle-bone unit of the forearm in
pediatric renal transplant recipients.
Background. Renal transplantation in children and adoles-
cents is associated with various skeletal complications. The
incidence of spontaneous fractures appears to be increased,
but the reasons for this are not entirely clear. Our objective
was therefore to evaluate macroscopic bone architecture, mass,
and strength by peripheral quantitative computed tomography
(pQCT), a method that is not influenced by size-related arti-
facts. In addition, we investigated the muscle-bone relationship
in these patients because under physiologic conditions bone
strength continually adapts to increasing mechanical loads, that
is, muscle force.
Methods. In 55 patients (41 males) aged 15.8 ± 4.1 years,
we evaluated in a cross-sectional study 4.9 ± 3.6 years after
renal grafting bone mass, density, geometry, and strength of the
radius, as well as forearm muscle size and strength, using pQCT
at the proximal and distal radius, radiography of the second
metacarpal shaft and hand dynamometry. Data were compared
to a large cohort (N = 350) of healthy children.
Results. Muscle mass and force were adequate for body size in
pediatric renal transplant recipients. However, the radial bone
was characterized by an inadequately thin cortex in relation to
muscular force, as shown by a reduced height-adjusted cortical
thickness both at the proximal (−0.83 ± 1.12 SDS) and dis-
tal radius (−0.52 ± 1.69 SDS), the metacarpal shaft (−0.54 ±
1.35 SDS), and by a reduced relative cortical area (−0.90 ±
1.13 SDS), while the mineralization of trabecular bone was un-
altered. As a consequence of cortical thinning, the Strength-
Strain Index that reflects the combined strength of trabecular
and cortical bone was reduced in these patients.
Conclusion. While bone mineral density of the forearm is not
decreased in pediatric renal transplant recipients, bone strength
in relation to muscular force is reduced. This alteration may
contribute to the increased propensity for fractures in these
patients.
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Osteopenia is a major osseous complication in adult
renal transplant recipients, and causes important long-
term morbidity because it places the patient at increased
risk for pathologic fractures [1]. The incidence of frac-
tures is increased five times among men, 18 times among
young women aged 25 to 44 years, and 34 times among
women aged 45 to 64 years [2]. These fractures occur
both at sites of high cancellous bone, such as the verte-
brae, and the peripheral skeleton [3]. Prospective stud-
ies in adult transplant recipients have demonstrated that
bone loss occurs early and rapidly following transplan-
tation of the kidney and other organs [4–6]. One re-
port, for example, evaluated bone mineral density and
bone histology in 20 living-related donor renal transplant
recipients treated with azathioprine, cyclosporine, and
low-dose prednisone [4]. These patients lost 6.8% of their
initial bone mass during the first six months, and devel-
oped a low-turnover bone disorder resembling that in-
duced by glucocorticoids. By 18 months, bone mass had
decreased 9.0% from baseline, and 60% of the patients
had bone density below the fracture threshold.
Multiple factors appear to contribute to these dis-
orders, including persistent uremia-induced abnormal-
ities in calcium homeostasis and acquired defects in
mineral metabolism induced by immunosuppressive
medications. Use of cyclosporine may diminish the risk
of these complications, in part by decreasing corticos-
teroid exposure. However, the incidence of osteopenia
and avascular necrosis is probably increasing because of
longer graft survival and, therefore, longer drug exposure.
Cyclosporine, which induces a high-turnover osteopenia
in rodents, also may contribute to bone loss, especially
in long-term survivors and in subjects treated only with
cyclosporine [7, 8].
Also in children and adolescents with functioning renal
transplants, various skeletal complications have been de-
scribed, including short stature, avascular bone necrosis,
osteopenia, and spontaneous fractures. The rate of atrau-
matic fractures in pediatric renal transplant recipients ap-
pears to be lower than in adults, although prospective
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studies on fracture incidence are lacking [9]. Neverthe-
less, an acquired post-transplant bone disease during
childhood and adolescence could predispose pediatric pa-
tients to the development of clinically apparent bone dis-
ease in adult life, particularly because the renal transplant
survival rate is steadily improving. There is, therefore, a
need to investigate bone mass and bone metabolism also
in pediatric renal transplant recipients.
Previous osteologic studies using dual-energy x-ray ab-
sorptiometry (DEXA) gained the impression that bone
mass is decreased in children and adolescents after renal
transplantation [10, 11]. However, these and several sub-
sequent studies neglect the fact that bone size might be
decreased in children and adolescents post-transplant be-
cause of their smaller body size. Smaller bones can be ex-
pected to weigh less, even if they are otherwise completely
normal. The finding that (short) children post-transplant
have lower bone mineral content or areal bone mineral
density than (taller) healthy age-matched controls was
therefore considered inconclusive.
Recent authors tried to circumvent this size-related
problem either by matching children post-transplant
with healthy controls of the same height or weight
[12–15], or by using mathematic algorithms to estimate
three-dimensional volumetric bone mineral density from
two-dimensional densitometric results [12]. Either way,
densitometric results were brought back to normality, and
it was concluded that in children after renal transplanta-
tion, bone mass is adequate for bone size.
Nevertheless, both of these approaches to adjust for
bone size are only valid if bone shape is the same in
children after renal transplantation as it is in controls.
It is uncertain whether this important condition is met,
given the many skeletal abnormalities in children post-
transplant. It is therefore preferable to study the skele-
ton of pediatric renal transplant recipients by methods
that can distinguish between effects of size and mass, and
do not require previous assumptions on bone shape. Pe-
ripheral quantitative computed tomography (pQCT) is
such a method. Thin tomographic sections of long bones
are analyzed, which allows for precise determination of
three-dimensional bone density. Further advantages of
this technique include the possibility to assess trabecu-
lar bone independently of cortical bone, and to evaluate
various measures of macroscopic bone geometry, which
can be combined into indices of bone strength [16, 17].
At least under experimental conditions, the information
on the bone’s architecture derived from pQCT measure-
ments provides better prediction of whole bone breaking
strength than the sole determination of areal bone min-
eral density by DEXA [18].
An adequate analysis of bone mass and strength must
include also the muscular system, because during statu-
ral growth, bone strength continually adapts to increas-
ing mechanical loads. Because the largest physiologic
loads on bones are created by muscle contraction, bone
strength needs to be adapted to muscle force [19, 20].
Some insight into this muscle-bone relationship can be
gained by performing pQCT analyses at limb sites where
the cross-sectional area of muscles (muscle CSA) is at
its maximum. In a single measurement run, both muscle
CSA and bone mass and geometry can be evaluated [21].
In the present study, we therefore used pQCT to eval-
uate bone mass, density, geometry, and strength of the
radius, as well as forearm muscle size and grip force in a
large group of pediatric renal transplant recipients. The
aims were to analyze bone characteristics by a method
that is not influenced by size-related artifacts, and to in-
vestigate the muscle-bone relationship in these patients.
METHODS
Patients
The study was designed as a prospective cross-sectional
study. All pediatric and adolescent patients with suc-
cessful kidney transplantation followed at the University
Children’s Hospital Heidelberg were screened. Exclusion
criteria were chronologic age <6 years and a concomitant
disease or mental retardation that prevented a regular
pQCT measurement without movement artifacts. Among
the 67 patients screened, 58 qualified, and 55 of those
agreed to participate. The study population comprised 55
(41 males) pediatric and adolescent patients after renal
transplantation. The patient characteristics are shown in
Table 1. Five patients (1 girl) had reduced renal transplant
function (CCR <50 mL/min/1.73 m2), 4 patients (1 girl)
had hyperfiltration (CCR >130 mL/min/1.73 m2). Mean
height SDS was −1.87 ± 1.14; 25 of 55 patients (45.5%)
were growth-retarded, defined as a height SDS value
below −2. All patients were Caucasian. The primary
renal disorders were classified as congenital (renal hypo-
/dysplasia (N = 11), recessive polycystic kidney disease
(N = 9), nephronophthisis (N = 6), obstructive or re-
flux nephropathy (N = 9), congenital nephrotic syndrome
(N = 3), renal tubular acidosis (N = 1), or acquired
(chronic glomerulonephritis (N = 5), hemolytic-uremic
syndrome (N = 1), vasculitis (N = 1), perinatal hypox-
emia (N = 2), renal amyloidosis (N = 2), and others (N =
5). Before transplantation, all but two patients had been
on dialysis for a median of 1.1 years (range, 0 to 5.6 years).
Only calcium-containing, phosphate-binding agents were
used during the dialysis treatment period. None of the pa-
tients had received aluminium-containing medications.
No patient had undergone partial or total parathyroidec-
tomy.
Forty-three patients had received cadaveric renal al-
lografts, 12 had undergone living-related transplanta-
tion. Immunosuppressive maintenance therapy consisted
of a calcineurin inhibitor [cyclosporine A (N = 49) or
tacrolimus (N = 6)] in all patients. The cyclosporine dose
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Table 1. Patient characteristics
Age at time Numbers Time interval
of renal of acute since
grafting rejection transplantation Calculated CCR
Patients Age years Bone age years years episodes years mL/min/1.73 m2 Height SDS
All patients 15.8 ± 4.09 14.1 ± 4.85 10.9 ± 4.21 0.97 ± 0.97 4.91 ± 3.59 86.3 ± 30.0 −1.87 ± 1.14
(N = 55) (5.96 to 25.0) (3.0 to 19.0) (2.28 to 16.3) (0 to 4) (0.27 to 16.1) (28.5 to 181) (−4.42 to 0.39)
Boys 16.5 ± 3.71 14.8 ± 4.51 11.4 ± 4.19 1.09 ± 1.00 5.10 ± 3.94 88.1 ± 32.4 −1.94 ± 1.02
(N = 41) (9.32 to 25.0) (4.5 to 19.0) (2.28 to 16.3) (0 to 4) (0.27 to 16.1) (28.5 to 181) (−4.36 to 0.39)
Girls 13.6 ± 4.48 12.0 ± 5.36 9.18 ± 3.89 0.64 ± 0.84 4.36 ± 2.35 80.8 ± 24.7 −1.67 ± 1.45
(N = 14) (5.96 to 21.8) (3.0 to 18.0) (2.65 to 15.8) (0 to 2) (0.87 to 9.43) (45.7 to 132) (−4.42 to 0.35)
Abbreviations are: SDS, standard deviation score; CCR, creatinine clearance. Data are mean ± SD, the range is given in parentheses.
was adjusted to maintain the whole-blood trough lev-
els between 80 and 160 mg/L. The annual cyclosporine
A dose averaged 1663 ± 787 (range 53 to 3324) mg/kg
body weight per year, corresponding to a mean daily dose
of 4.6 mg/kg; the cumulative cyclosporine A dose was
8855 ± 8363 (range 68.5 to 32736) mg/kg body weight.
The tacrolimus dose was adjusted to maintain the whole-
blood trough levels between 3 and 8 mg/L. The cal-
cineurin inhibitor was given in conjunction with either
methylprednisolone (N = 48, given on alternate days in
7 of 48) or deflazacort (N = 7, given on alternate days in
2 of 7). An equivalence of 1 mg methylprednisolone to
1.5 mg deflazacort was assumed. Two of 55 patients
(3.6%) were on a steroid-free immunosuppressive reg-
imen at the time of examination. Methylprednisolone
was started at 60 mg/m2 IV and gradually tapered to
4 mg/m2 per day orally during the following six weeks.
Acute rejection episodes were usually treated with an
intravenous bolus of methylprednisolone. For the cal-
culation of the annual and cumulative glucocorticoid
dose, the deflazacort dose was converted to the equiv-
alent methylprednisolone dose, and data for both drugs
were summarized as “glucocorticoid” data. The annual
dosage of glucocorticoids was 63.3 ± 38.7 (range 7.0 to
277) mg/kg body weight per year; the cumulative gluco-
corticoid dose was 246 ± 170 (range 57.7 to 961) mg/kg
body weight. Fifty-one patients received a triple regimen
with either azathioprine (1 to 2 mg/kg per day; N = 15)
or mycophenolate mofetil (600 mg/m2 b.i.d.; N = 36).
Three patients were on vitamin D supplements, three on
calcium supplements, none on phosphate supplements.
Three patients received treatment with recombinant hu-
man growth hormone (rhGH) at time of examination.
Three patients were treated with furosemide, six patients
with hydrochlorothiazide. One patient had experienced
a fracture of the radius, and none had aseptic bone necro-
sis. No patient suffered from bone pain at time of pQCT
measurement.
All biochemical and anthropometric data were ob-
tained on the day of pQCT measurements. Informed con-
sent was obtained from all patients and/or their parents.
The study protocol was approved by the Ethics Commit-
tee of the University of Heidelberg.
Methods
Anthropometry. Height was measured in a stand-
ing position, using a wall-mounted Holtain stadiome-
ter (Holtain, Crymych, Dyfed, UK) with a precision of
0.1 cm. Weight was determined to the nearest 0.1 kg us-
ing an electronic scale (Seca, Germany). The stage of
sexual development was determined by physical exam-
ination using the grading system defined by Tanner for
pubic hair and breast development [22].
Peripheral quantitative computed tomography. Two
sites of the nondominant radius were analyzed by pQCT
(XCT-2000 scanner; Stratec, Inc., Pforzheim, Germany),
the distal metaphysis (4% site) and the proximal diaph-
ysis (65% site), as described in detail before [16, 23, 24].
The scanner was equipped with a low-energy (38 kV)
x-ray tube. The radiation dose for a single scan was 0.3
mSv, the effective dose for the forearm about 0.1 mSv
from a radiation source of 45 kV at 150 lA. Measure-
ment at the metaphyseal site was carried out at the lo-
cation of the radius, for which distance to the distal ra-
dial articular surface corresponded to 4% of forearm
length. The diaphyseal measurement was performed at
a site for which the distance to the ulnar styloid pro-
cess corresponded to 65% of forearm length. This site
of measurement was chosen to analyze the forearm at
its maximum circumference. At both sites, a 2-mm-thick
single tomographic slice was sampled at a voxel size of
0.4 mm.
At the metaphyseal (“4%”) site, bone mineral content
(BMC), total bone mineral density (BMD), trabecular
BMD, and Strength-Strain Index were calculated by the
manufacturer’s software. Cortical thickness was derived
mathematically as described [17]. BMC represents the
mass of mineral per millimeter of slice thickness. Total
BMD is defined as the mean mineral density of the total
cross-section [21]. The Strength-Strain Index describes
the strength of bone toward bending and torsion, and is
calculated as the product of section modulus and volu-
metric cortical BMD normalized to the maximal physio-
logic cortical BMD of human bones [26]. It reflects the
combined strength of trabecular and cortical bone, and
has been shown to provide a good estimate of the me-
chanical strength of human radii [16].
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At the diaphyseal (“65%”) site, cortical CSA of the
radius was determined by detecting the outer and inner
cortical bone contour at a threshold of 710 mg/cm3. Vox-
els peripheral of the outer edges of the bone with an ab-
sorptiometric density between 20 and 60 mg/cm3 were
interpreted as representing muscle. Cortical CSA, total
BMC, total BMD, and muscle CSA were calculated by the
manufacturer’s software. Cortical thickness and relative
cortical CSA (as the ratio between cortical and total area
in percent) were derived from these primary measures as
described [24].
We also performed measurements of bone mineral
density and bone mineral content of the total skeleton
and the lumbar spine by DEXA in this cohort of patients.
These data will be reported elsewhere.
Grip force. Maximal isometric grip force of the
nondominant hand was determined with a stan-
dard adjustable-handle Jamar dynamometer (Preston,
Jackson, MI, USA) [27]. The handle was adjusted so that
the line of the subject’s proximal interphalangeal joints
rested exactly on top of it. Consequently, setting 1 of the
Jamar dynamometer was used for the younger children,
and setting 2 for most of the older children and adoles-
cents; setting 3 was used in some of the adolescents and
adults, whereas settings 4 and 5 were never used. The
subject was seated with the shoulder adducted and neu-
trally rotated. The dynamometer was held freely, with-
out support. The elbow was flexed at 90◦, and care was
taken that it did not touch the trunk. The forearm was
in a neutral position, and the wrist was held at between
0 and 30◦ dorsiflexion, and between 0 and 15◦ ulnar de-
viation. The subjects were told to put maximal force on
the dynamometer. The maximal value of two trials was
noted. We use the term “grip force” instead of the more
widely used “grip strength” because “force” is a term that
is clearly defined by physics, whereas “strength” is used
inconsistently in the medical literature, denoting a vari-
ety of different parameters, including force, torque, and
power.
Radiogrammetry. X-ray pictures of the nondominant
hand were a dorso-palmar projection on a non-screen
film. The thickness of the second metacarpal was mea-
sured using a special type of pinpoint caliper accurate to
0.1 mm at the thinnest point of the second metacarpal
shaft [28]. Cortical thickness was obtained by subtracting
the medullary diameter from the diameter of the entire
second metacarpal, as described [28].
Biochemical and hormonal parameters. Serum cal-
cium, phosphate, and creatinine were determined by
an automated Hitachi analyzer. Intact parathyroid hor-
mone (PTH) was measured by a chemiluminescence
assay (DPC Biermann, Bad Nauheim, Germany); the ref-
erence range of the assay is 1.3 to 7.6 pmol/L. Total 25-
hydroxy-vitamin D3 was determined by enzyme-linked
immunosorbent assay (ELISA) (ImmunDiagnostik
Bensheim, Germany); the reference range is 25 to 240
nmol/L. Serum bone alkaline phosphatase activity was
measured by an ELISA technique with a commercially
available kit (Alkphase B; Metra Biosystems, Inc., Moun-
tain View, CA, USA). Intra- and interassay CV were 4%
to 7% and 6% to 12%, respectively. Urinary deoxypyridi-
noline concentration was measured by an chemilumines-
cence assay (Immulite-Pyrilinks-D; DPC Biermann, Inc.)
in an aliquot derived from a 24-hour urine collection and
expressed per mmol creatinine. Intra- and interassay CV
were 6% to 9% and 6% to 15%, respectively. Patient data
were compared to pediatric reference data [29, 30]. Ran-
dom plasma estradiol was measured by a commercially
available automatic analysis (Elecsys, Roche Diagnostics,
Mannheim, Germany). Plasma testosterone levels were
measured by radioimmunoassay following extraction and
chromatography, as described [31, 32].
Statistical analysis
To obtain age-independent estimates of body size,
height was converted to standard deviation score (SDS)
values, related to age- and gender-specific means and SD
of the Zurich longitudinal growth study [17]. The pQCT
and dynamometer results were compared with those in a
German reference population using identical methodol-
ogy. These were participants of the Dortmund Nutritional
and Anthropometric Longitudinally Designed Study, an
observational study investigating the interrelations of nu-
trition, growth, and metabolism in 350 healthy children
and adolescents, aged 6 to 22 years. The results in this
reference population have been described before [16, 17,
21, 23, 24]. As reference values for the radiogrammetry
data, we used the normative data derived from a col-
lective containing 329 (153 females) healthy subjects be-
tween 3 and 74 years of age [28]. Results in pediatric
renal transplant recipients were converted into age- and
gender-specific SDS values using the formula: SD score
= [(test result for a patient) – (age-specific mean in ref-
erence population)]/(age-specific SD in reference popu-
lation). To take into account the reduced body size of
the patients, height-related SDS values were calculated
in addition.
Results are expressed as mean ± SD, if not indicated
otherwise. Normal distribution of the data was assessed
by the Shapiro-Wilks test. To evaluate whether a param-
eter was significantly different from the result in controls,
the difference of the mean SD score to zero was assessed.
A significant difference was assumed when the 95% con-
fidence interval of the mean SD score did not include
zero. For comparisons between two groups, Student t test
was used. Correlations between variables were assessed
using univariate linear regression analysis. Test for inter-
action between independent variables was performed by
two-way analysis of variance (ANOVA). Throughout, a
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Table 2. Bone density parameters and bone mineral content at the proximal [diaphyseal (65%) site] and the distal radius [metaphyseal (4%) site]
measured by pQCT
Parameter All patients (N = 55) Boys (N = 41) Girls (N = 14)
Total bone mineral density65% mg·cm−3 SDS-CA −0.16 ± 1.06 −0.24 ± 1.10 0.10 ± 0.92
(−2.00 to 2.06) (−2.00 to 2.06) (−1.56 to 1.65)
SDS-HA 0.54 ± 1.18c 0.53 ± 1.25b 0.59 ± 0.97a
(−3.07 to 3.70) (−3.07 to 3.70) (−0.89 to 2.68)
Cortical bone mineral density65% mg·cm−3 SDS-CA −0.20 ± 1.51 −0.16 ± 1.58 −0.35 ± 1.29
(−4.92 to 1.93) (−4.92 to 1.93) (−3.60 to 1.39)
SDS-HA 0.89 ± 1.40c 0.83 ± 1.38c 1.02 ± 1.51b
(−2.72 to 3.15) (−2.72 to 2.73) (−1.49 to 3.15)
Bone mineral content65% mg·mm−1 SDS-CA −1.14 ± 1.15c −1.25 ± 1.14c −0.73 ± 1.15a
(−3.62 to 1.49) (−3.62 to 1.49) (−3.36 to 0.43)
SDS-HA 0.28 ± 0.96 0.34 ± 1.03 0.08 ± 0.67
(−1.68 to 3.03) (−1.68 to 3.03) (−1.08 to 1.02)
Total bone mineral density4% mg·cm−3 SDS-CA −0.80 ± 1.19c −0.98 ± 1.20c −0.20 ± 1.03
(−3.35 to 2.22) (−3.35 to 2.22) (−1.61 to 1.27)
SDS-HA 0.27 ± 1.29 0.22 ± 1.27 0.43 ± 1.37
(−2.32 to 3.32) (−2.15 to 3.32) (−2.32 to 2.24)
Trabecular bone mineral density4% mg·cm−3 SDS-CA 0.22 ± 1.26 0.09 ± 1.27 0.65 ± 1.17
(−1.97 to 2.87) (−1.97 to 2.87) (−1.07 to 2.71)
SDS-HA 0.46 ± 1.32 0.40 ± 1.36 0.66 ± 1.15
(−2.04 to 3.18) (−2.04 to 3.18) (−1.24 to 2.58)
Abbreviations are: pQCT, peripheral quantitative computed tomography; SDS-CA, standard deviation score related to chronological age; SDS-HA, standard
deviation score related to height age. Data are mean ± SD, the range is given in parentheses.
aP < 0.05 patients vs. controls; bP < 0.01 patients vs. controls; cP < 0.001 patients vs. controls.
P value below 0.05 was considered significant. All statisti-
cal analyses were performed using SigmaStat version 2.0
or SPSS version 8.0 (SPSS Science, Chicago, IL, USA).
RESULTS
Bone mineral density and content
Bone density parameters measured by pQCT at the
proximal and distal radius are shown in Table 2. Data
are compared both to age-matched and height-matched
healthy children and the respective SDS were calculated.
The age-adjusted total, as well as cortical bone mineral
density at the proximal forearm (diaphyseal site), were
not significantly different from control, while the total
bone mineral density at the distal radius (metaphyseal
site) was significantly decreased. When the reduced body
size of these individuals was taken into account by calcu-
lation of SDS values related to height age, a different pat-
tern was obtained (Table 2). The height-adjusted total and
cortical bone mineral density at the diaphyseal (65%) site
were significantly increased compared to control, while
the total bone mineral density at the distal (4%) radius
was not significantly different from control. The volumet-
ric trabecular bone density was comparable to control, in-
dependently whether the measurements were related to
age- or height-matched controls. Height-adjusted bone
density parameters were comparable between boys and
girls. The mean age-adjusted bone mineral content in pa-
tients was significantly decreased compared to control,
whereas the mean height-adjusted bone mineral content
was not significantly different from control (Table 2).
Bone geometry and strength
Table 3 shows the analysis of parameters of the cortical
bone compartment measured by pQCT at the proximal
and distal radius and of the metacarpal cortical thickness
measured by radiogrammetry. Cortical thickness both
at the proximal and distal radius were significantly de-
creased compared to control. This difference was less
pronounced, but remained statistically significant, when
patient data were adjusted to height age instead of
chronologic age (Table 3). The relative cortical area at
the proximal site was decreased to a comparable ex-
tent. There was an inverse relation between the height-
adjusted relative cortical area and the time period since
renal grafting, indicating that this loss of cortical bone
may be progressive after renal transplantation (Fig. 1).
The marrow area at the 65% site was increased to a higher
extent than the total cross-sectional area (Table 3). These
data indicate that decreased cortical thickness is mainly
due to increased endosteal dimensions.
Due to this decrease in cortical thickness, the mean
Strength-Strain Index, a parameter combining bone ge-
ometry and density, was significantly decreased both at
the proximal and distal radius in these patients (Table 3),
although the volumetric total bone mineral density was
normal (Table 2). Consistent with the data derived from
pQCT measurements, there was also a moderately de-
creased cortical thickness of the metacarpal bone mea-
sured by radiogrammetry (Table 3). In girls, the decrease
in the height-adjusted cortical thickness at the distal
radius, the Strength-Strain Index, and the metacarpal
cortical thickness did not reach statistical significance
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Table 3. Bone geometry and strength of the proximal (65%) and distal (4%) radius measured by pQCT, and metacarpal cortical thickness
measured by conventional radiogrammetry
Parameter All patients (N = 55) Boys (N = 41) Girls (N = 14)
Total cross-sectional area65% mm2 SDS-CA −0.11 ± 1.41 −0.12 ± 1.54 0.04 ± 0.91
(−2.86 to 3.85) (−2.86 to 3.85) (−1.30 to 1.30)
SDS-HA 0.78 ± 1.31c 0.93 ± 1.40c 0.49 ± 0.61
(−1.66 to 3.90) (−1.57 to 3.90) (−0.16 to 1.68)
Marrow area65% mm2 SDS-CA 1.11 ± 1.69c 1.19 ± 1.89c 1.00 ± 0.98b
(−1.31 to 6.03) (−1.31 to 6.03) (−0.14 to 3.50)
SDS-HA 1.29 ± 1.73c 1.45 ± 1.90c 0.76 ± 0.68a
(−1.16 to 6.03) (−1.16 to 6.03) (−0.09 to 2.80)
Cortical thickness65% mm SDS-CA −1.60 ± 1.03c −1.68 ± 1.09c −1.34 ± 0.84c
(−3.91 to 0.79) (−3.91 to 0.79) (−1.34 to 0.06)
SDS-HA −0.83 ± 1.12c −0.86 ± 1.23c −0.73 ± 0.74b
(−4.56 to 1.34) (−4.56 to 1.34) (−1.83 to 0.08)
Relative cortical area65% % SDS-CA −1.62 ± 1.17c −1.76 ± 1.26c −1.54 ± 1.48c
(−3.85 to 0.43) (−3.85 to 0.43) (−6.00 to –0.36)
SDS-HA −0.90 ± 1.13c −0.97 ± 1.25c −0.92 ± 1.04b
(−4.57 to 1.42) (−4.57 to 1.42) (−3.89 to 0.12)
Strength-Strain Index65% mm3 SDS-CA −1.46 ± 0.99c −1.61 ± 0.96c,d −0.93 ± 0.94b,d
(−3.8 to 0.97) (−3.8 to 0.97) (−2.39 to 0.25)
SDS-HA −0.35 ± 0.96a −0.42 ± 1.02b −0.10 ± 0.52
(−2.44 to 2.16) (−2.44 to 2.16) (−0.90 to 0.52)
Cortical thickness4% mm SDS-CA −1.71 ± 1.29c −1.88 ± 1.35c,d −1.12 ± 0.91c,d
(−4.78 to 2.41) (−4.78 to 2.41) (−2.88 to 0.77)
SDS-HA −0.52 ± 1.69b −0.60 ± 1.85b −0.25 ± 0.95
(−2.54 to 3.21) (−4.92 to 3.31) (−1.91 to 1.35)
Strength-Strain Index4% mm3 SDS-CA −1.89 ± 0.96c −2.06 ± 0.94c,d −1.32 ± 0.83c,d
(−4.08 to 0.26) (−4.08 to 0.21) (−2.38 to 0.26)
SDS-HA −0.49 ± 1.24b −0.48 ± 1.32a −0.51 ± 0.99a
(−3.41 to 3.10) (−3.41 to 3.10) (−1.78 to 1.14)
Metacarpal cortical thickness mm SDS-CA −1.38 ± 1.58c −1.52 ± 1.47c,d −0.91 ± 1.89b,d
(−5.70 to 3.71) (−5.70 to 0.62) (−3.12 to 3.71)
SDS-HA −0.54 ± 1.35c −0.59 ± 1.02c −0.38 ± 2.15
(−3.26 to 3.71) (−3.26 to 0.87) (−2.01 to 3.71)
Abbreviations are: pQCT, peripheral quantitative computed tomography; SDS-CA, standard deviation score related to chronological age; SDS-HA, standard
deviation score related to height age. Data are mean ± SD, the range is given in parenthesis.
aP < 0.05 patients vs. controls; bP < 0.01 patients vs. controls; cP < 0.001 patients vs. controls; dP < 0.05 boys vs. girls.
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Fig. 1. Height-adjusted relative cortical area (RCA) at the proximal
forearm as a function of time since renal transplantation. There was a
significant inverse correlation (r = −0.35, P < 0.02).
(Table 3). This observation may not necessarily reflect
a true biologic difference, but may be due to the lower
number of female (N = 14) compared to male (N = 41)
patients in our study. None of the parameters derived by
pQCT measurements were correlated with the cumula-
tive or annual glucocorticoid dosage, the cyclosporine A
dosage, or with transplant function, as estimated by the
calculated creatinine clearance. The group of patients on
deflazacort, on alternate day steroids and those without
steroids, summarizing 29% of the whole study popula-
tion, did not differ from the other patients with respect
to indices investigated.
In healthy children, there is a linear correlation be-
tween cortical thickness and cortical density (Fig. 2), in-
dicating that under physiologic conditions, a thick cortex
is also more dense. In pediatric renal transplant recip-
ients, the slope of the regression line between cortical
thickness and cortical density was significantly steeper
than in controls (Fig. 2), indicating that the relative thin
cortex in these patients has an inadequately high density.
Statistical interaction between cortical thickness and the
respective group of probands (patients or controls) was
excluded by two-way ANOVA.
The functional muscle-bone relationship
Children and adolescents after renal transplanta-
tion had a significantly reduced age-adjusted muscle
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Fig. 2. Cortical density as a function of cortical thickness at the prox-
imal forearm in pediatric renal transplant recipients () and controls
(). The slope of the regression line for patients (dotted line) was sig-
nificantly steeper (P = 0.035) than for controls (straight line). Patients,
N = 55, r = 0.74, P < 0.0001, y = 849 + 121×. Controls, N = 355, r =
0.74, P < 0.0001, y = 868 + 91.9×.
cross-sectional area and grip force (Table 4). However,
the respective height-adjusted values were in the nor-
mal range, indicating that muscle mass and muscle force
are adequate for body size in these patients (Table 4).
Figure 3A shows that the relationship between muscle
cross-sectional area and body height is comparable be-
tween patients and controls. In Figure 3B, only puber-
tal and postpubertal boys after renal transplantation are
compared to controls matched for height and pubertal
development. This analysis confirms that the muscle
cross-sectional area in male patients after renal trans-
plantation is comparable to controls of the same height
and pubertal development.
As observed in healthy controls (r = 0.66, P < 0.001)
[27], there was a highly significant linear correlation be-
tween muscle cross-sectional area and grip force in renal
transplant patients (r = 0.73, P < 0.001) (Fig. 4). The
respective slopes of these regression lines were not sig-
nificantly different between patients and controls, indi-
cating that the relationship between muscle size and per-
formance is preserved in patients post-transplant. Sta-
tistical interaction between muscle cross-sectional area
and the respective group of probands (patients or con-
trols) was excluded by two-way ANOVA. There was no
relationship between the height-adjusted muscular cross-
sectional area and the cumulative or annual glucocorti-
coid dose.
In healthy children, cortical thickness and bone
strength are tightly related to the corresponding muscle
cross-sectional area (Fig. 5), indicating that bone size and
strength adapt adequately to local muscle force. In pe-
diatric renal transplant recipients, cortical thickness and
bone strength were also correlated with the correspond-
ing muscle cross-sectional area. However, in both analy-
ses, the slopes of the respective regression lines in patients
were significantly (P < 0.001) less steep than in controls
(Fig. 5). This indicates that cortical thickness and bone
strength in these patients are not adequately adapted to
muscle force.
We have previously proposed the ratio bone mineral
content (BMC) per muscle cross-sectional area (CSA) as
an index of the functional muscle-bone unit, and have es-
tablished age-dependent pediatric reference data for this
ratio [33]. In pediatric renal transplant recipients, most
individual data points both in boys and in girls fell within
these reference ranges (Fig. 6). The mean SDS value for
the BMC/muscle CSA ratio (mean 0.36 ± 1.58; −2.08 to
5.31 SDS) was not significantly different from control.
The elevated values of the BMC/muscle CSA ratio in
eight individual male patients post-transplant were due to
a relatively low height-adjusted muscle CSA (mean −1.44
± 0.86; range −2.64 to −0.28 SDS), while the height-
adjusted BMC values in these seven patients (mean
1.04 ± 0.91; range −0.23 to 2.17 SDS) were relatively
high.
Biochemical and hormonal evaluation
The analysis of hormonal and biochemical parameters
of calcium-phosphate metabolism is shown in Table 5.
Mean PTH levels were in the high normal range, 15
of 54 patients (28%) had mild secondary hyperparathy-
roidism. Fifteen percent of patients had subnormal
25-(OH)-vitamin D3 serum levels. Mean serum calcium
levels were normal; only one patient was hypocalcemic,
seven of 53 (13%) had mild hypercalcemia. By use of
the urinary calcium/creatinine ratio, none of the patients
was hypercalciuric; two of 35 (6%) had an elevated uri-
nary calcium excretion rate. While serum phosphate lev-
els were normal in the majority of patients, the mean
maximal tubular reabsorption of phosphorus was slightly
below the normal range; 16 patients (33%) had a de-
creased maximal tubular reabsorption of phosphorus.
Plasma PTH levels were not correlated with the maxi-
mal tubular reabsorption of phosphorus; mean plasma
PTH in patients with a decreased maximal tubular reab-
sorption of phosphorus was not different (5.54 ± 4.09;
range 0.1 to 15.0 pmol/L) to those in patients with nor-
mal maximal tubular reabsorption of phosphorus (5.53 ±
3.55; range 1.0 to 14.2 pmol/L). Plasma PTH levels were
also not correlated with the urinary desoxypyridino-
line/creatinine ratio as a marker of bone resorption. Pa-
tients with hyperparathyroidism (N = 15) tended (P =
0.06) to have a lower height-adjusted cortical thickness
at the diaphyseal site (−1.42 ± 1.61 SDS) than those with
normal plasma PTH (−0.67 ± 0.89 SDS). For the whole
study population, none of the biochemical or hormonal
parameters of calcium-phosphate metabolism were
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Table 4. Analysis of muscle cross-sectional area and grip force
Parameter All patients (N = 55) Boys (N = 41) Girls (N = 14)
Muscle cross-sectional area mm2 SDS-CA −1.26 ± 1.37c −1.47 ± 1.19c,d −0.49 ± 1.75d
(−3.96 to 3.00) (−3.96 to 2.10) (−3.48 to 3.00)
SDS-HA 0.05 ± 1.26 0.01 ± 1.14 0.19 ± 1.69
(−2.64 to 3.80) (−2.64 to 3.10) (−1.64 to 3.80)
Grip force N SDS-CA −1.60 ± 1.11c −1.73 ± 1.07c −1.17 ± 1.17c
(−3.71 to 0.95) (−3.71 to 0.95) (−3.24 to 0.63)
SDS-HA −0.04 ± 1.11 −0.01 ± 1.15 −0.13 ± 1.01
(−2.54 to 3.21) (−2.54 to 3.21) (−1.95 to 1.54)
Abbreviations are: SDS-CA, standard deviation score related to chronological age; SDS-HA, standard deviation score related to height age. Data are mean ± SD,
the range is given in parentheses.
aP < 0.05 patients vs. controls; bP < 0.01 patients vs. controls; cP < 0.001 patients vs. controls; dP < 0.05 boys vs. girls.
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Fig. 3. (A) Muscle cross-sectional area at the proximal forearm in pe-
diatric renal transplant recipients () and controls (), as a function of
body height. The slope of the regression line for patients (dotted line)
was comparable to that for controls (straight line). Patients, N = 55,
r = 0.75, P < 0.0001, y = −2396 + 32.4×; controls, N = 355, r = 0.76,
P < 0.0001, r = 0.76; y = −2027 + 29×. (B) Muscle cross-sectional area
at the proximal forearm in male pubertal and postpubertal pediatric
renal transplant recipients () and controls (), matched for height
and pubertal development, as a function of body height. The slope of
the regression line for patients (dotted line) was comparable to that for
controls (straight line) (P = 0.65). Patients, N = 34, r = 0.69, P < 0.001;
y = −4838 + 52.8×; controls, N = 25, r = 0.53, P < 0.001; y = −4562+
47.7×.
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Fig. 4. Grip force as a function of muscle cross-sectional area (CSA)
in pediatric renal transplant recipients () and controls (). The slope
of the regression line for patients (dotted line) was not significantly
different from that for controls (straight line) (P = 0.42). Patients, N =
55, r = 0.73, P < 0.0001, y = 16.9 + 0.07×; controls, N = 355, r = 0.66,
P < 0.0001; y = 55.98 + 0.05×.
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Fig. 5. (A) Cortical thickness as a function of muscle cross-sectional
area at the proximal forearm in pediatric renal transplant recipients
() and controls (). Both parameters were obtained by pQCT-
measurements at the proximal (65%) site of the nondominant radius.
The slope of the regression line for patients (dotted line) was signifi-
cantly less steep (P < 0.001) than for controls (straight line). Patients,
N = 55, r = 0.69, P < 0.0001, y = 0.5 + 0.0004×. Controls, N = 355,
r = 0.79, P < 0.0001, y = 0.14 + 0.0006×. (B) Bone strength index as
a function of muscle cross-sectional area in pediatric renal transplant
recipients () and controls (). Both parameters were obtained by
pQCT measurements at the 65% site of the nondominant radius. The
slope of the regression line for patients (dotted line) was significantly
less steep (P < 0.001) than for controls (straight line). Patients, N = 55,
r = 0.81, P < 0.0001, y = −36.5 + 0.07×. Controls, N = 355, r = 0.90,
P < 0.0001, y = −49.5 + 0.10×.
correlated with parameters of bone density, geometry, or
strength. If the five patients with reduced renal trans-
plant function were excluded from the analysis, there
was a weak correlation between height-adjusted corti-
cal thickness at the diaphyseal site and serum alkaline
phosphatase activity (r = 0.35, P = 0.03).
Data for serum bone-specific alkaline phosphatase ac-
tivity as a marker of bone formation and the urinary
desoxypyridinoline/creatinine ratio as a marker of bone
resorption are depicted in Table 6. In the vast majority
of patients (94%), the activity of bone-specific alkaline
phosphatase was within the normal range. Eight of 42
patients (19%) had an elevated urinary desoxypyridi-
noline/creatinine ratio. While plasma testosterone
levels were within the normal range in the majority of
patients, three of nine female patients (33%) had sub-
normal plasma estradiol levels (Table 7). There was no
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Fig. 6. Ratio of bone mineral content and
muscle cross-sectional area at the proximal
forearm in male (A) and female (B) pediatric
renal transplant recipients related to chrono-
logic age. Bold lines indicate age- and gender-
dependent mean values of healthy children
and adolescents, thin lines ± 2 SD.
Table 5. Hormonal and biochemical parameters of calcium-phosphate metabolism
(5th to 95th percentile) No. of patients with values
Parameter Patient data Normal range outside the normal range
Parathyroid hormone pmol/L 6.12 ± 4.79 1.3 to 7.6 2 of 54 <1.3
(0.10 to 21.9) 15 of 54 >7.6
25-(OH)-vitamin D3 nmol/L 62.1 ± 63.4 25 to 240 8 of 54 <25
(6.00 to 447) 1 of 54 >240
Serum calcium mmol/L 2.49 ± 0.15 2.1 to 2.65 1 of 53 <2.1
(1.92 to 2.83) 7 of 53 >2.65
Serum phosphate pre- and pubertal mmol/L 1.32 ± 0.20 1.1 to 2.0 5 of 40 <1.1
(0.94 to 1.69)
Postpubertal mmol/L 1.14 ± 0.26 0.8 to 1.5 1 of 14 <0.8
(0.64 to 1.79) 1 of 14 >1.5
Urinary calcium/creatinine ratio mg/mg 0.04 ± 0.03 <0.2 –
(0.00 to 0.14)
Urinary calcium excretiona lmol/kg/d 37.9 ± 35.7 20 to 90 13 of 35 <20
(6.00 to 189) 2 of 35 >90
Maximal tubular reabsorption of phosphorus % 81.8 ± 9.7 82 to 90 16 of 49 <82
(58.7 to 98.8) 6 of 49 >90
Data are mean ± SD, the range is given in parenthesis.
aUrinary calcium excretion was calculated only in patients with a creatinine clearance >60 mL/min/1.73 m2 body surface area (N = 35).
correlation of bone markers or gonadal steroid hormone
levels with any of the parameters derived by pQCT mea-
surements.
DISCUSSION
This is the first detailed study of the macroscopic bone
architecture and the functional muscle-bone unit in a
large cohort of pediatric renal transplant recipients. The
main findings are the following. First, the radial bone of
pediatric renal transplant recipients is characterized by an
inadequately thin cortex in relation to muscular force, as
shown by a reduced cortical thickness both at the prox-
imal and distal radius and the metacarpal shaft and by
a reduced relative cortical area. This alteration could be
consequence of a reduced periosteal bone formation rate
(decreased modeling) or increased endosteal remodeling
or a combination of these factors. Second, this thin cortex
has an inadequately high density, indicating a disturbed
intracortical remodeling rate.
The question arises whether this alteration of corti-
cal bone is a primary bone disorder or a secondary phe-
nomenon due to reduced muscular force. According to
the Utah paradigm of skeletal physiology, the control of
postnatal bone strength and mass strongly depends on
the largest mechanical load on bones, that is, the mus-
cular system [34, 35]. The strong correlation between
muscle strength and bone structure, as also observed in
the present study both in controls and in patients post-
transplant, can be interpreted as a reflection of bone
adaptation to mechanical loading. The combined analysis
of the muscle and bone system, the so-called “functional
muscle-bone unit,” may therefore allow differentiation
between primary and secondary bone diseases [36]. The
primary bone diseases have their cause in a direct dis-
order of the bone cells and/or the synthesized matrix,
which may be due to inborn errors of metabolism, hor-
monal disturbances, metabolic alterations (e.g., uremia),
drugs such as glucocorticoids, and others. The secondary
bone diseases arise because of muscle disorders that lead
to an inactivity of the bones. Applying this paradigm to
our data in children and adolescents post-transplant, the
observed changes can be interpreted as follows. The al-
teration of a thin cortex at least of the radius and the
metacarpal shaft appears to be a primary disturbance of
the skeletal system and not a secondary phenomenon due
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Table 6. Serum levels of bone specific alkaline phosphatase as a marker of bone formation and the urinary desoxypyridinoline/creatinine ratio as
a marker of bone resorption, stratified according to the developmental stage of the patients
Developmental Patient Normal range No. of patients with
Parameter stage Gender data (5th to 95th percentile) values outside the normal range
Bone-specific alkaline Prepubertal Male 67.0 13 to 145 –
phosphatase U/L (N = 7) (N = 3) (62.6 to 77.5) –
Female 83.9 43 to 147 1 of 4 <43
(N = 4) (41.8 to 111)
Pubertal Male 84.2 48 to 300 2 of 13 <48
(N = 18) (N = 13) (42.3 to 141)
Female 128 15 to 159 –
(N = 5) (63.9 to 141)
Postpubertal Male 45.0 0 to 134 –
(N = 26) (N = 23) (29.3 to 118)
Female 33.9 11 to 45 –
(N = 3) (22.4 to 34.1)
Urinary desoxypyridinoline/ Prepubertal Male 19.0 3.6 to 26.5 –
creatinine ratio nmol/mmol (N = 5) (N = 3) (12.7 to 23.5)
Female 26.7 4.6 to 33.9 1 of 2 >33.9
(N = 2) (15.8 to 37.6)
Pubertal Male 14.9 0.8 to 28.2 1 of 12 >28.2
(N = 17) (N = 12) (7.8 to 47.9)
Female 19.0 2.6 to 20.6 2 of 5 >20.6
(N = 5) (12.5 to 26.3)
Postpubertal Male 8.60 0 to 17.8 4 of 17 >17.8
(N = 20) (N = 17) (3.2 to 45.6)
Female 7.03 0.7 to 13.5 –
(N = 3) (5.30 to 8.50)
Data are median and range.
Table 7. Plasma levels of testosterone and estrodiol, stratified according to the developmental stage
Developmental Patient Normal range No. of patients with
Parameter stage Gender data (5th to 95th percentile) values outside the normal range
Testosterone ng/dL Pubertal Male 225 20 to 970 –
(N = 18) (N = 13) (27.3 to 820)
Female 25.0 7 to 38 1 of 5 >38
(N = 5) (9.10 to 57.6)
Postpubertal Male 548 250 to 1000 1 of 23 <250
(N = 26) (N = 23) (173 to 1025) 1 of 23 >1000
Female 42.5 20 to 80 –
(N = 3) (37.6 to 46.5)
Estradiol ng/dL Pubertal and postpubertal Male 25.0 10 to 45 2 of 29 >45
(N = 38) (N = 29) (8.00 to 131) 1 of 29 <10
Female 45.0 40 to 350 3 of 9 <40
(N = 9) (14.0 to 411)
Data are median and range.
to changes in the muscular system, because both muscle
size and force in these patients were adequate for body
size. The latter observation is reassuring and indicates
that physical (e.g., inactivation due to a chronic illness)
and/or metabolic (e.g., decreased renal function, protein
catabolism due to the glucocorticoid medication) factors
with a potentially negative impact on the muscular system
did not play a major role.
In adult patients, post-transplant bone loss involves
both preexisting risk factors (such as hyperparathy-
roidism) and the adverse effects of immunosuppressive
therapy [1]. Glucocorticoid-induced suppression of bone
formation is the most important factor in the genesis of
early and long-term bone loss [1, 37, 38]. Steroids are
directly toxic to osteoblasts, and lead to increased osteo-
clast activity [39]. They also have other effects that pro-
mote calcium loss and the development of osteopenia.
These include decreased calcium absorption in the gut,
increased urinary calcium excretion, reduced gonadal
hormone production, diminished insulin-like growth
factor–I (IGF-I) production, and decreased sensitivity to
PTH [39].
In this study in pediatric renal transplant recipients,
we were not able to identify a single factor that could
be related by statistical analysis to the reduced thick-
ness of cortical bone, indicating that the pathophysiology
of this alteration is complex. The reduction of cortical
thickness could be due to accelerated bone resorption
at least in a subgroup of patients (19%), who showed
an elevated urinary desoxypyridinoline/creatinine ratio
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as a marker of bone resorption. We also observed mild
hyperparathyroidism in 28% of this patient cohort, con-
sistent with previous reports in pediatric [12, 13] and
adult renal transplant recipients [40]. The reason for these
slightly elevated plasma PTH levels post-transplant are
either a persistent secondary hyperparathyroidism due
to preexisting uremia and partial nodular transformation
of the parathyroid gland to monoclonal growth, and/or
a de novo hyperparathyroidism due to chronic allograft
nephropathy [40–42]. The net effect of continuous hy-
perparathyroidism on the skeleton is a reduction and
thinning of cortical bone [43]. Our observation that the
thinning of cortical bone was not correlated with plasma
PTH levels is consistent with a previous bone histomor-
phometric study in adult renal transplant recipients [38],
indicating that plasma PTH does not necessarily reflect
the degree of bone remodeling. Because of ethical con-
cerns we did not perform bone biopsies in our study.
Sanchez et al [13] performed iliac crest bone biopsy in
47 pediatric renal transplant recipients (mean age 12 ±
2.0 years) with stable graft function 3.2 ± 1.7 years after
transplantation: 66% of patients had normal bone forma-
tion, 23% had mild hyperparathyroidism, and 11% had
adynamic skeletal lesions. Macroscopic bone geometry
was not investigated in this study.
Our finding of a reduced cortical thickness both at
the proximal and distal radius and the metacarpal shaft
could also be due to a reduced periosteal bone formation
rate, that is, decreased bone modeling. Cortical bone is
widened during growth by osteoblastic bone formation
on the outer bone surface, the periosteum. A major hor-
monal modulator of periosteal growth is the growth hor-
mone (GH)/IGF axis. It has recently been shown that
mice deficient for liver IGF-I (LID), acid labile sub-
unit (ALS) knockout mice (KO), and the double gene
disruption LID+ALSKO mice have a reduced femoral
periosteal circumference, a smaller cross-sectional area,
and a thinner cortical bone compared with control mice
[44]. These data indicate that circulating IGF-I is critical
for the modeling of bone, particularly periosteal growth.
We have previously shown that circulating IGF bioactiv-
ity is significantly reduced in pediatric renal transplant
recipients [45]. Hence, one hormonal factor that might
contribute to the reduced cortical thickness in this pa-
tient population is functional IGF deficiency. Because
therapy with recombinant human GH is associated with
a normalization of plasma IGF bioactivity in children
post-transplant [45], it will be interesting to investigate
in future studies whether this treatment modality has the
potential to restore cortical thickness in these patients.
In contrast to these alterations of cortical bone, the
volumetric trabecular bone mineral density at the dis-
tal radius in patients post-transplant was not different
from control. Similarly, the total bone mineral con-
tent at the proximal radius was normal, independent of
whether the data were compared to height-matched con-
trols or related to the corresponding muscle size. These
data indicate that bone mineralization of the forearm is
adequate in pediatric renal transplant recipients. This
finding is consistent with previous observations of normal
bone mineral density and bone mineral content of the to-
tal skeleton and of the lumbar spine by DEXA, when
the methodologic problem of small bone size in these pa-
tients was adequately addressed either by adjusting the
data to height age or by estimating three-dimensional
volumetric bone mineral density from two-dimensional
densitometric results by use of a mathematical algorithm
[12–14]. The reason why the skeleton in pediatric patients
is at a lower risk to develop post-transplant osteopenia
than in adult patients is not entirely clear. It may be that
the growing skeleton adapts to current mechanical re-
quirements faster that the fully-grown skeleton. In this
context, it is noteworthy that according to recent exper-
imental data areas of the juvenile skeleton are not com-
pletely remodeled, but actually replaced in toto through
skeletal growth [46]. As a juvenile bone enlarges and the
medullary cavity expands, bone formed early in life, re-
gardless of quality, is gradually resorbed and replaced
by new bone through modeling [46]. By this mechanism,
insufficient bone mineralization due to high-dose gluco-
corticoids in the early period post-transplant may be re-
paired in the maintenance period, in which glucocorti-
coids are usually tapered to a low-dose regimen below
the Cushing threshold. This hypothesis will be tested in
future longitudinal studies that will compare bone mass
and macroscopic bone geometry in the de novo and the
maintenance period post-transplant.
An additional finding of our study was that the thin cor-
tex of radial bone in children posttransplant has an inade-
quately high bone mineral density. Cortical bone mineral
density is defined as the mass of mineral obtained be-
tween the periosteal and endocortical surfaces divided by
the volume of this compartment. It is an integrated mea-
sure of both cortical porosity and mean material density
of cortical bone. The metabolic activity of cortical bone
(intracortical remodeling) increases cortical porosity and
decreases the mean material density of cortical bone. Intr-
cortical remodeling replaces “old” bone, which has a high
material density, with young bone, which has a low mate-
rial density [25]. Our results therefore suggest that intra-
cortical remodeling is lower in children post-transplant
than in healthy controls. A possible explanation for
this observation is that the calcium store in cortical bone
is increased in patients post-transplant due to previous
high-dose calcitriol therapy for the control of hyper-
parathyroidism during the period of end-stage renal dis-
ease. On the other hand, the resolution of preexisting
hyperparathyroidism following transplantation may con-
tribute to this increased cortical bone density. Further
longitudinal investigations on cortical bone in children
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with CRF before and after renal transplantation is re-
quired to substantiate these hypotheses.
Two previous studies investigated by pQCT bone min-
eral density of the radius in pediatric renal transplant
recipients. Behnke et al reported a reduced cortical bone
density at the distal and proximal radius and an increased
volumetric trabecular bone mineral density in 24 pedi-
atric patients after renal transplantation compared to 12
age-matched controls; however, these differences did not
reach statistical significance [47]. While the latter find-
ing is in accordance with our observation, the result of a
reduced cortical bone density is difficult to interpret be-
cause these data were not compared to height-matched
controls. It is therefore likely that the observed differ-
ences are solely due to differences in bone size. Reusz
et al observed normal volumetric total, trabecular, and
cortical bone mineral density at the distal radius in 31
children 5.4 years after renal transplantation compared
to height-matched controls [48]. While the first two find-
ings are in agreement with our data, the latter observation
may not be valid because cortical bone mineral density
at the distal radius cannot be reliably measured by pQCT
due to the partial volume effect [49, 50].
CONCLUSION
This study shows that the radial bone of pediatric renal
transplant recipients is characterized by an inadequately
thin cortex in relation to muscular force, as shown by
a reduced cortical thickness both at the proximal and
distal radius and the metacarpal shaft and by a reduced
relative cortical area, while the bone mineral density of
trabecular bone is unaltered. As a consequence of cor-
tical thinning, the Strength-Strain Index that reflects the
combined strength of trabecular and cortical bone is re-
duced in these patients. This reduced bone strength is
likely to contribute to the increased propensity for frac-
tures in young renal transplant recipients. This assump-
tion about the value of pQCT measurements in assessing
bone health in this patient population will be tested in
future studies against clinical outcome measures such as
fractures.
Reprint requests to Burkhard To¨nshoff, M.D., Ph.D., University Chil-
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